104 related articles for article (PubMed ID: 21206361)
1. Efficacy of bupropion XR in treatment-resistant elderly patients: a case series study.
Bergman J; Miodownik C; Palatnik A; Lerner V
Clin Neuropharmacol; 2011; 34(1):17-20. PubMed ID: 21206361
[TBL] [Abstract][Full Text] [Related]
2. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
3. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
Papakostas GI; Worthington JJ; Iosifescu DV; Kinrys G; Burns AM; Fisher LB; Homberger CH; Mischoulon D; Fava M
Depress Anxiety; 2006; 23(3):178-81. PubMed ID: 16528701
[TBL] [Abstract][Full Text] [Related]
4. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
[TBL] [Abstract][Full Text] [Related]
5. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.
Hewett K; Chrzanowski W; Jokinen R; Felgentreff R; Shrivastava RK; Gee MD; Wightman DS; O'Leary MC; Millen LS; Leon MC; Briggs MA; Krishen A; Modell JG
J Psychopharmacol; 2010 Apr; 24(4):521-9. PubMed ID: 19164492
[TBL] [Abstract][Full Text] [Related]
6. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
[TBL] [Abstract][Full Text] [Related]
7. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
Jamerson BD; Krishnan KR; Roberts J; Krishen A; Modell JG
Psychopharmacol Bull; 2003; 37(2):67-78. PubMed ID: 14566216
[TBL] [Abstract][Full Text] [Related]
8. HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.
Bech P; Boyer P; Germain JM; Padmanabhan K; Haudiquet V; Pitrosky B; Tourian KA
Pharmacopsychiatry; 2010 Nov; 43(7):271-6. PubMed ID: 20830664
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder.
Feighner J; Hendrickson G; Miller L; Stern W
J Clin Psychopharmacol; 1986 Feb; 6(1):27-32. PubMed ID: 3081600
[TBL] [Abstract][Full Text] [Related]
11. Combined antidepressant treatment: a risk factor for switching in bipolar patients.
Gabbay V; O'Dowd MA; Asnis GM
J Clin Psychiatry; 2002 Apr; 63(4):367; author reply 367-8. PubMed ID: 12000212
[No Abstract] [Full Text] [Related]
12. Safety and efficacy of bupropion in elderly patients: preliminary observations.
Kane JM; Cole K; Sarantakos S; Howard A; Borenstein M
J Clin Psychiatry; 1983 May; 44(5 Pt 2):134-6. PubMed ID: 6406442
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
15. Treatment of psychotic depression in the elderly compared with nonpsychotic depression.
Kok R; Heeren T; Nolen W
J Clin Psychopharmacol; 2010 Aug; 30(4):465-7. PubMed ID: 20631567
[No Abstract] [Full Text] [Related]
16. Efficacy of bupropion in tricyclic-resistant or intolerant patients.
Stern WC; Harto-Truax N; Bauer N
J Clin Psychiatry; 1983 May; 44(5 Pt 2):148-52. PubMed ID: 6406447
[TBL] [Abstract][Full Text] [Related]
17. White matter hyperintensity progression and late-life depression outcomes.
Taylor WD; Steffens DC; MacFall JR; McQuoid DR; Payne ME; Provenzale JM; Krishnan KR
Arch Gen Psychiatry; 2003 Nov; 60(11):1090-6. PubMed ID: 14609884
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
[TBL] [Abstract][Full Text] [Related]
19. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study.
Bot M; Pouwer F; Assies J; Jansen EH; Diamant M; Snoek FJ; Beekman AT; de Jonge P
J Affect Disord; 2010 Oct; 126(1-2):282-6. PubMed ID: 20466431
[TBL] [Abstract][Full Text] [Related]
20. Bupropion-induced neck and shoulder pain.
Sansone RA; Sansone LA
Pharmacopsychiatry; 2009 Sep; 42(5):203-4. PubMed ID: 19724984
[No Abstract] [Full Text] [Related]
[Next] [New Search]
